The hypothesis of this study was that palbociclib would improve clinical outcomes, given the preclinical data supporting the use of CDK4/6 inhibitors in prostate cancer detailed above and the anticipated parallels between prostate cancer and breast cancer where clinical benefit has been clearly established. This evidence concerns the gene CDK4 and breast cancer.